-5%
Zeropain (Ketorolac Tromethamine) is a powerful short-term analgesic for managing moderate to severe pain. Due to its side effect profile (especially GI and renal), it is typically limited to short-term use (≤5 days). Patients must be closely monitored for gastrointestinal, renal, and cardiovascular complications, particularly the elderly or those with preexisting conditions.
- Adults:
Recommended doses depend on the formulation and route (oral, IV, IM). Usually not exceeding 5 days of treatment due to potential toxicity. - Children:
Not recommended for patients under 16 years.
Zeropain is a pyrrolo-pyrrole NSAID used for its potent analgesic (pain-relieving) properties. It functions primarily by inhibiting prostaglandin synthesis via the cyclooxygenase (COX) enzyme, leading to its pain-relief effects. However, it exhibits minimal anti-inflammatory properties at its usual analgesic doses.
- Chemical Composition:
5-benzoyle-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1).
Pharmacokinetics
- Absorption: Rapidly absorbed after administration.
- Protein Binding: Highly protein-bound.
- Metabolism: Primarily metabolized in the liver.
- Excretion: Excreted through urine as metabolites and some unchanged drugs.
- Linear Pharmacokinetics: Drug levels are proportional to dose.